These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29916030)

  • 1. [The importance of molecular imaging (PET) in the diagnostics of dementia].
    Tscheuschler M; Gebest M; Jessen F; Drzezga A
    Nervenarzt; 2018 Jul; 89(7):843-856. PubMed ID: 29916030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular imaging of dementia.
    Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
    Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications.
    Albin RL; Fisher-Hubbard A; Shanmugasundaram K; Koeppe RA; Burke JF; Camelo-Piragua S; Lieberman AP; Giordani B; Frey KA
    Ann Neurol; 2015 Nov; 78(5):824-30. PubMed ID: 26183692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain
    Nobili F; Arbizu J; Bouwman F; Drzezga A; Agosta F; Nestor P; Walker Z; Boccardi M;
    Eur J Neurol; 2018 Oct; 25(10):1201-1217. PubMed ID: 29932266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
    Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
    Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
    Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia.
    Eisenmenger LB; Huo EJ; Hoffman JM; Minoshima S; Matesan MC; Lewis DH; Lopresti BJ; Mathis CA; Okonkwo DO; Mountz JM
    Semin Nucl Med; 2016 Jan; 46(1):57-87. PubMed ID: 26687858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current and future prospects of nuclear medicine in dementia].
    Ito K; Inui Y; Kizawa T; Kimura Y; Kato T
    Rinsho Shinkeigaku; 2017 Sep; 57(9):479-484. PubMed ID: 28804110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education.
    Johnson KA; Minoshima S; Bohnen NI; Donohoe KJ; Foster NL; Herscovitch P; Karlawish JH; Rowe CC; Hedrick S; Pappas V; Carrillo MC; Hartley DM
    J Nucl Med; 2013 Jul; 54(7):1011-3. PubMed ID: 23753186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid imaging with PET in early Alzheimer disease diagnosis.
    Rowe CC; Villemagne VL
    Med Clin North Am; 2013 May; 97(3):377-98. PubMed ID: 23642577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.
    Weidman DA; Zamrini E; Sabbagh MN; Jacobson S; Burke A; Belden C; Powell J; Bhalla N; Roontiva A; Kuang X; Luo J; Chen K; Riggs G; Burke W
    Neurocase; 2017 Feb; 23(1):41-51. PubMed ID: 28376695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid imaging.
    Villemagne VL; Rowe CC
    Int Psychogeriatr; 2011 Sep; 23 Suppl 2():S41-9. PubMed ID: 21729418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.